Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Portfolio News / By Karina Tin August 9, 2023 Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Read More »
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin August 8, 2023 Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Read More »
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin August 8, 2023 eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Read More »
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Portfolio News / By Karina Tin August 4, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights Portfolio News / By Karina Tin August 3, 2023 NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights Read More »
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Portfolio News / By Karina Tin August 1, 2023 Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Read More »
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer Portfolio News / By Karina Tin July 31, 2023 Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer Read More »
Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies Portfolio News / By Karina Tin July 27, 2023 Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies Read More »
Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development Portfolio News / By Karina Tin July 26, 2023 Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development Read More »
Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B Portfolio News / By Karina Tin July 19, 2023 Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B Read More »
